precisionmedicineonline2d
Amgen's Lumakras, Vectibix Net FDA Approval in KRAS G12C-Mutant Colorectal Cancer
The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.
Amgen: FDA Approves Lumakras (sotorasib) In Combination With Vectibix (panitumumab) For Chemorefractory Kras G12c-mutated Metastatic Colorectal Cancer
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...
hospitalhealthcare3d
Lung cancer pathway insights from Dr Zaheer Mangera part 1: early diagnosis and screening
Dr Zaheer Mangera shares insights into the lung cancer pathway and the benefits and challenges of early diagnosis and lung ...
healthandpharma3d
FDA Approves Sotorasib and Panitumumab Combination: Doubling Survival for KRAS G12C-Mutated Colorectal Cancer
The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...
Cautiously Optimistic: ProKidney’s Hold Rating Amid Accelerated Pathway and Trial Developments
Analyst Judah Frommer from Morgan Stanley maintained a Hold rating on ProKidney (PROK – Research Report) and keeping the price target at ...
Le Lézard6d
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...